Seven key genes, namely, CEACAM1, CEACAM6, IL1RN, PLAUR, STAT1, TGFB1, and THBS2, offer clinicians potential biomarkers warranting further analysis for IPMN stratification and treatment targets for invasive PDAC. This evidence concerns the gene CEACAM1 and pancreatic intraductal papillary-mucinous neoplasm.